Status:
NOT_YET_RECRUITING
Asprosin in Breast Cancer
Lead Sponsor:
Marina Hanna Thabet Ghobrial
Conditions:
Breast Cancer
Eligibility:
All Genders
18-60 years
Brief Summary
To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the rou...
Eligibility Criteria
Inclusion
- \-
- Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow:
- Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.
Exclusion
- 1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06592560
Start Date
October 1 2024
End Date
October 1 2025
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.